ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 1503

Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands Might Help to Avoid Unnecessary Lip Biopsy in Patients with Sicca Syndrome
Abstract Number: 1927

Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA
Abstract Number: 1536

Ultrasound as an Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Early Rheumatoid Arthritis, TOVERA – a Longitudinal Study
Abstract Number: 1552

Ultrasound Doppler Enthesitis Shows Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients
Abstract Number: 1925

Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Abstract Number: 1541

Ultrasound in Knee Osteoarthritis: Reader Performance, Sonographic Features, and Correlation with Radiographic Findings
Abstract Number: 1533

Ultrasound Joint Inflammation but Not Disease Activity Score at 28 Joints Is Reflective of the Severity of Joint Damage in Patients with Rheumatoid Arthritis
Abstract Number: 1252

Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an OMERACT Ultrasound Working Group Study
Abstract Number: 1546

Ultrasound, Magnetic Resonance Imaging and Radiography of the Fingers’ Joints of Psoriatic Arthritis Patients
Abstract Number: 0764

Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Abstract Number: 1171

Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
Abstract Number: 0080

Understanding Ankylosing Spondylitis –
Abstract Number: 1378

Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Abstract Number: 1980

Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Abstract Number: 0135

Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Abstract Number: 1275

Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
Abstract Number: 1689

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abstract Number: 1193

Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
Abstract Number: 1345

Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
Abstract Number: 0209

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
Abstract Number: 0207

Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
Abstract Number: 0784

Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
Abstract Number: 0817

Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Abstract Number: 0664

Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Abstract Number: 1816

Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Abstract Number: 0029

Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Abstract Number: 0936

Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Abstract Number: 0872

Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Abstract Number: 1384

Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
Abstract Number: 1614

Use of a Best Practice Alert to Encourage Transition Planning and Readiness
Abstract Number: 1597

Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Abstract Number: 1782

Use of a Patient-reported Survey to Document Contraceptive Use and Interest in Pregnancy to Identify Patients with Unmet Pregnancy Prevention and Planning Needs
Abstract Number: 0441

Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus
Abstract Number: 0643

Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Abstract Number: 1785

Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Abstract Number: 1894

Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
Abstract Number: 0942

Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
Abstract Number: 1204

Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA
Abstract Number: 1233

Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Abstract Number: 0105

Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Abstract Number: 1646

Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events
Abstract Number: 0160

Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Abstract Number: 1166

Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Abstract Number: 0344

Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
Abstract Number: 1537

Usefulness of Ultrasound Assessment of Sarcopenia in Patients with Rheumatoid Arthritis
Abstract Number: 1175

Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease
Abstract Number: 1276

Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Abstract Number: 0476

Using Consensus Building to Guide Rheumatology Curriculum Development for Internal Medicine Residents
Abstract Number: 0258

Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
Abstract Number: 1595

Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
Abstract Number: 0351

Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Abstract Number: 1208

Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Abstract Number: 0555

Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database
Abstract Number: 1962

Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic
Abstract Number: 0170

Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 1304

Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].